Pfizer's first quarter, confirmed five trading days ago, printed $14.45 billion in revenue, $0.75 adjusted earnings per share, and zero share repurchases. [1] The single line that moves on Wall Street is the Padcev number: $591 million, up 39 percent year on year, against a consensus of $542 million. [2] The full-year 2026 guide stays at $59.5 to $62.5 billion. The buyback line stays at nothing.

The paper's account at Day Four read the print as pharma joining the disciplined cohort — Apple, Berkshire, and Pfizer all sitting on the not-deploying side of a market the consensus calls expensive. Day Five adds clinical. The Phase 3 EV-304 KEYNOTE-B15 readout for Padcev plus pembrolizumab in muscle-invasive bladder cancer landed on the same week as Apple's record-day buyback execution today and Berkshire's first 13F under Greg Abel on Thursday. [3] The asset that moved the print is the asset that moved the pipeline. The Seagen acquisition Pfizer paid $43 billion for in 2023 is now the firm's load-bearing oncology story.

What the zero-buyback line says, two quarters running, is that Pfizer's capital allocation in 2026 is paying down debt and funding the pipeline, not defending the share count. That is the same posture Apple committed to in February when it sized the buyback envelope without raising the dividend, and the same posture Berkshire is widely expected to hold on Thursday. The disciplined cohort this paper has tracked through the Iran-war-premium tape and the Cerebras pricing window now has a pharma anchor in the print. The undisciplined cohort — Tesla's $573 million related-party set inside the SpaceX S-1 window — prices on the same trading band this week. The market sorts them out by Friday.

-- THEO KAPLAN, San Francisco